Search Result

Results for "

dopamine (DA)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dopamine Receptor (27) Dopamine Transporter (8) 5-HT Receptor (5) Adrenergic Receptor (7) Calcium Channel (1) Cannabinoid Receptor (1) Drug Metabolite (1) Endogenous Metabolite (2) FKBP (1) HIV (1) Interleukin Related (1) Isotope-Labeled Compounds (3) mAChR (1) mGluR (1) Monoamine Oxidase (1) Monoamine Transporter (1) nAChR (6) Opioid Receptor (2) Potassium Channel (2) Serotonin Transporter (13) Sodium Channel (3) Somatostatin Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Endocrinology (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (53)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Dopamine Receptor Dopamine Transporter Dopamine β-hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0979

Lobeline hydrochloride α-Lobeline hydrochloride; L-Lobeline hydrochloride	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-16736

Centanafadine EB-1020	Adrenergic Receptor Dopamine Transporter Serotonin Transporter	Neurological Disease Endocrinology
Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC₅₀s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

HY-16736A

Centanafadine hydrochloride EB-1020 hydrochloride	Adrenergic Receptor Dopamine Transporter Serotonin Transporter	Neurological Disease Endocrinology
Centanafadine (hydrochloride) is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC₅₀s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

HY-113257

Dopamine 4-sulfate DA-4S; dopamine 4-Sulfate	Drug Metabolite	Neurological Disease
Dopamine 4-sulfate (DA-4S) is an inactive metabolite of the catecholamine dopamine. It is formed from dopamine by the sulfotransferase (SULT) isoform SULT1A3. Dopamine 4-O-sulfate is found at lower levels in the brain and circulation than dopamine 3-O-sulfate.

HY-160440A

VU6021625	mAChR	Neurological Disease
VU6021625 is a selective antagonist muscarinic acetylcholine receptors (mAChRs), with the IC₅₀ value of 0.44 nM, 57 nM for human M4 and rat M4, respectively .

HY-118461

PD 120697	Dopamine Receptor	Neurological Disease
PD 120697 is an orally active **dopamine (DA)** agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .

HY-B1423

Lobeline α-Lobeline; L-Lobeline	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) is a brain-penetrant nicotinic receptor agonist. Lobeline increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline is effective in smoking cessation .

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

HY-118706

PD 118440	Dopamine Receptor	Neurological Disease
PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .

HY-B0979R

Lobeline hydrochloride (Standard)	nAChR Dopamine Transporter	Neurological Disease
Lobeline (hydrochloride) (Standard) is the analytical standard of Lobeline (hydrochloride). This product is intended for research and analytical applications. Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-121650A

ADTN hydrobromide	Dopamine Receptor	Neurological Disease
ADTN hydrobromide is a long-acting *dopamine* agonist. ADTN hydrobromide significantly decreases the behavioral visual threshold of DA-IPC-depleted zebrafish .

HY-145454A

Preclamol (-)-3-PPP	Dopamine Receptor	Neurological Disease
Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. Preclamol inhibits the locomotor activity of mice and rats in low doses .

HY-W010265

Butyrophenone 1-Phenylbutan-1-one; 1-Phenyl-1-butanone	Dopamine Receptor	Neurological Disease
Butyrophenone (1-Phenylbutan-1-one) is a dopamine receptor (DA Receptor) antagonist and can be used in research on mental disorders .

HY-145454

(R)-Preclamol (+)-3-PPP	Dopamine Receptor	Neurological Disease
(R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses .

HY-121685

Tipepidine	Potassium Channel	Neurological Disease
Tipepidine reversibly inhibits dopamine (DA) D₂ receptor-mediated GIRK currents (I_DA(GIRK)) with an IC₅₀ of 7.0 μM. Tipepidine subsequently activates VTA dopamine neuron . Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect .

HY-121685A

Tipepidine hydrochloride 1 Publications Verification	Potassium Channel	Neurological Disease
Tipepidine hydrochloride reversibly inhibits dopamine (DA) D₂ receptor-mediated GIRK currents (I_DA(GIRK)) with an IC₅₀ of 7.0 μM. Tipepidine hydrochloride subsequently activates VTA dopamine neuron . Tipepidine hydrochloride, a non-narcotic antitussive, exerts an antidepressant-like effect .

HY-123837

MLS1082	Dopamine Receptor	Neurological Disease
MLS1082 is a pyrimidone-based *D1-like dopamine* receptor positive allosteric modulator, with an EC₅₀** of 123 nM for DA-stimulated G protein signaling .

HY-122495

rel-Quinpirole dihydrochloride rel-LY 171555 dihydrochloride; rel-LY 141865 dihydrochloride	Dopamine Receptor	Neurological Disease
rel-Quinpirole (rel-LY 171555) dihydrochloride, an ergot compound, is a selective dopamine (DA) D2 receptor agonist. rel-Quinpirole dihydrochloride can be used for research on neurological diseases .

HY-W014728

N-Methyldopamine hydrochloride	Dopamine Receptor	Cardiovascular Disease Neurological Disease
N-Methyldopamine hydrochloride is a precursor of adrenaline in the adrenal medulla. N-Methyldopamine hydrochloride is a modification of the dopamine (DA), and retains agonist activity at the DA1 receptor. N-Methyldopamine hydrochloride remains capable of universal surface coating and secondary reactions using the surface catechols. N-Methyldopamine hydrochloride can be used for heart failure research .

HY-B1110

Nomifensine 5 Publications Verification (±)-Nomifensine; Nomifensin	Dopamine Receptor Adrenergic Receptor	Neurological Disease
Nomifensine ((±)-Nomifensine) is a potent norepinephrine (NE) and **dopamine (DA) reuptake inhibitor. Nomifensine inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC₅₀ values of 6.6 nM, 48 nM and 830 nM, and K_i** values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine shows low or ineffective binding activity to dopamine D2, α1-adrenergic, 5-HT2, and muscarinic receptors. Nomifensine has antidepressive effects .

HY-B1110A

Nomifensine maleate 5 Publications Verification (±)-Nomifensine maleate; Nomifensin maleate	Dopamine Receptor Adrenergic Receptor	Neurological Disease
Nomifensine ((±)-Nomifensine) maleate is a potent norepinephrine (NE) and **dopamine (DA) reuptake inhibitor. Nomifensine maleate inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC₅₀ values of 6.6 nM, 48 nM and 830 nM, and K_i** values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine maleate shows low or ineffective binding activity to dopamine D2, α1-adrenergic, 5-HT2, and muscarinic receptors. Nomifensine maleate has antidepressive effects .

HY-108448

N-Oleoyldopamine OLDA	TRP Channel	Cardiovascular Disease
N-Oleoyldopamine (OLDA) is a product of condensation of oleic acid and dopamine (DA) and an endogenous TRPV1 selective agonist. N-Oleoyldopamine (OLDA) can crosses the blood-brain barrier. N-oleoyl-dopamine protects the heart against ischemia-reperfusion injury via activation of TRPV1 .

HY-12244

BB-22	Dopamine Receptor Cannabinoid Receptor	Neurological Disease
BB-22 is a cannabinoid wih dopamine (DA) stimulant properties. BB-22 shows affinity to CB1 receptors with a K_i value of 0.11 nM and an EC₅₀ value of 2.9 nM .

HY-10684

Pridopidine ACR16; ASP2314; FR310826	Dopamine Receptor	Neurological Disease
Pridopidine, a *dopamine* (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with K_i between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.

HY-117436

R(+)-6-Bromo-APB hydrobromide	Dopamine Receptor	Cardiovascular Disease
R(+)-6-Bromo-APB hydrobromide is a **dopamine (DA)** agonist. R(+)-6-Bromo-APB hydrobromide increased the expression of µ opioid receptor (MOR) mRNA in the nucleus accumbens .

HY-111210

Pridopidine hydrochloride ACR16 hydrochloride; ASP2314 hydrochloride; FR310826 hydrochloride	Dopamine Receptor	Neurological Disease
Pridopidine (ACR16) hydrochloride, a *dopamine* (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with K_i between 70 and 80 nM, which is ~100-fold higher than its affinity toward D2R.

HY-113316A

(±)-Salsolinol hydrochloride	Endogenous Metabolite Opioid Receptor	Neurological Disease
(±)-Salsolinol hydrochloride is the hydrochloride form of (±)-Salsolinol (HY-113316). (±)-Salsolinol hydrochloride is a Dopamine (HY-B0451)-derived endogenous metabolite. (±)-Salsolinol hydrochloride activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of *dopamine* (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .

HY-138806

PAQ	Calcium Channel	Neurological Disease
PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells .

HY-103147

Mesulergine hydrochloride CU32-085 hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Mesulergine (CU32-085) hydrochloride is a potent 5-HT2C antagonist and **dopamine (DA)** agonist. Mesulergine hydrochloride presentes hyperphagia. Mesulergine hydrochloride has the potential for the research of cognitive processes .

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-W010265R

Butyrophenone (Standard)	Dopamine Receptor	Neurological Disease
Butyrophenone (Standard) is the analytical standard of Butyrophenone. This product is intended for research and analytical applications. Butyrophenone (1-Phenylbutan-1-one) is a dopamine receptor (DA Receptor) antagonist and can be used in research on mental disorders .

HY-B1110S

Nomifensine-d3 maleate (±)-Nomifensine-d₃ maleate; Nomifensin-d₃ maleate	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor	Neurological Disease
Nomifensine-d₃ ((±)-Nomifensine-d₃) maleate is the deuterium labeled Nomifensine maleate (HY-B1110A). Nomifensine ((±)-Nomifensine) is a potent norepinephrine (NE) and **dopamine (DA) reuptake inhibitor. Nomifensine inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC₅₀ values of 6.6 nM, 48 nM and 830 nM, and K_i** values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine shows low or ineffective binding activity to dopamine D2, α1-adrenergic, 5-HT2, and muscarinic receptors. Nomifensine has antidepressive effects .

HY-107674

bPiDDB	nAChR	Neurological Disease
bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC₅₀=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-N2003

D-Tetrahydropalmatine	Dopamine Receptor	Metabolic Disease
D-Tetrahydropalmatine is an isoquinoline alkaloid, mainly in the genus Corydalis . D-Tetrahydropalmatine is a **dopamine (DA) receptor antagonist with preferential affinity toward the D1 receptors . D-Tetrahydropalmatine is a potent organic cation transporter 1 (OCT1)** inhibitor .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-P10435

KEMPFPKYPVEP	Dopamine Receptor	Neurological Disease
KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model .

HY-148867

UCM-1306 2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl	Dopamine Receptor	Neurological Disease
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .

HY-W013353

(RS)-Salsolinol hydrobromide	Endogenous Metabolite Opioid Receptor	Neurological Disease
(RS)-Salsolinol hydrobromide is the hydrobromide form of (±)-Salsolinol (HY-113316). (RS)-Salsolinol hydrobromide is a Dopamine (HY-B0451)-derived endogenous metabolite. (RS)-Salsolinol hydrobromide activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .

HY-152170

bPiDI	nAChR	Neurological Disease
bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-109112

Brilaroxazine RP5063	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-17385

Atomoxetine hydrochloride 4 Publications Verification Tomoxetine hydrochloride; (R)-Tomoxetine hydrochloride; LY 139603	Adrenergic Receptor Serotonin Transporter Sodium Channel	Neurological Disease Cancer
Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with K_i values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na ⁺ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-128121

MLS1547	Dopamine Receptor	Neurological Disease
MLS1547 is a highly efficacious *G protein-biased dopamine* D2 receptor (D2R) agonist (K_i=1.2 μM). MLS1547 stimulates D2R G protein-mediated signaling (EC₅₀*=0.37 μM in a calcium mobilization assay). MLS1547 acts as an antagonist for dopamine* (DA)-stimulated β-arrestin recruitment to the D2R (IC₅₀=9.9 μM) .

HY-109112R

Brilaroxazine (Standard)	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (Standard) is the analytical standard of Brilaroxazine. This product is intended for research and analytical applications. Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-156331

VU6004909	mGluR	Neurological Disease
VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC₅₀s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy .

HY-W061043

DOV-216,303	Serotonin Transporter Dopamine Transporter	Neurological Disease
DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC₅₀ values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .

HY-B0602

Desvenlafaxine O-Desmethylvenlafaxine	Serotonin Transporter	Neurological Disease
Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC₅₀ values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .

HY-101377A

R(+)-8-OH-DPAT hydrobromide (R)-8-Hydroxy-2-dipropylaminotetralin hydrobromide	5-HT Receptor	Neurological Disease
R(+)-8-OH-DPAT ((R)-8-Hydroxy-2-dipropylaminotetralin) hydrobromide is a potent 5-HT_1A agonist. R(+)-8-OH-DPAT potentiates SUL (HY-B1059)-induced dopamine (DA) release in the medial prefrontal cortex (mPFC) .

HY-107370

Atomoxetine Tomoxetine; (R)-Tomoxetine	Serotonin Transporter Sodium Channel	Neurological Disease Cancer
Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with K_i values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DA_EX and NE_EX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na ⁺ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-B0602A

Desvenlafaxine succinate hydrate O-Desmethylvenlafaxine succinate hydrate; Desvenlafaxine succinate monohydrate	Serotonin Transporter	Neurological Disease
Desvenlafaxine succinate hydrate, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC₅₀ values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine succinate hydrate shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .

HY-14472

Tesofensine NS-2330	Dopamine Transporter Serotonin Transporter	Metabolic Disease
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC₅₀=6.5 nM), norepinephrine (NE;IC₅₀=1.7 nM), and serotonin (5-HT;IC₅₀=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .

Cat. No.	Product Name

HY-L165

Dopamine Receptor Compound Library

222 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 222 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Cat. No.	Product Name	Target	Research Area

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-P10435

KEMPFPKYPVEP	Dopamine Receptor	Neurological Disease
KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0979

Lobeline hydrochloride α-Lobeline hydrochloride; L-Lobeline hydrochloride	Alkaloids Structural Classification Source classification Campanulaceae Pyridine Alkaloids Plants Lobelia chinensis Lour.	nAChR Dopamine Transporter
Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-N2003

D-Tetrahydropalmatine	Alkaloids Structural Classification Corydalis yanhusuo W. T. Wang Classification of Application Fields Source classification Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields Papaveraceae	Dopamine Receptor
D-Tetrahydropalmatine is an isoquinoline alkaloid, mainly in the genus Corydalis . D-Tetrahydropalmatine is a **dopamine (DA) receptor antagonist with preferential affinity toward the D1 receptors . D-Tetrahydropalmatine is a potent organic cation transporter 1 (OCT1)** inhibitor .

HY-B1423

Lobeline α-Lobeline; L-Lobeline	Structural Classification Alkaloids Other Alkaloids Source classification Campanulaceae Plants Lobelia chinensis Lour.	nAChR Dopamine Transporter
Lobeline (α-Lobeline) is a brain-penetrant nicotinic receptor agonist. Lobeline increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline is effective in smoking cessation .

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	Alkaloids Structural Classification other families Source classification Pyridine Alkaloids Plants Endogenous metabolite	nAChR Dopamine Transporter
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

HY-B0979R

Lobeline hydrochloride (Standard)	Alkaloids Structural Classification Source classification Campanulaceae Pyridine Alkaloids Plants Lobelia chinensis Lour.	nAChR Dopamine Transporter
Lobeline (hydrochloride) (Standard) is the analytical standard of Lobeline (hydrochloride). This product is intended for research and analytical applications. Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-N2426R

Clerodendrin (Standard)	Clerodendrum trichotomum Thunb. Structural Classification Flavonoids Verbenaceae Plants Isoflavones	Interleukin Related
Desvenlafaxine (Standard) is the analytical standard of Desvenlafaxine. This product is intended for research and analytical applications. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .

Cat. No.	Product Name	Chemical Structure

HY-B0602S2

Desvenlafaxine-d6

Desvenlafaxine-d₆ is deuterium labeled Desvenlafaxine. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter[1][2].

HY-B1110S

Nomifensine-d3 maleate

Nomifensine-d₃ ((±)-Nomifensine-d₃) maleate is the deuterium labeled Nomifensine maleate (HY-B1110A). Nomifensine ((±)-Nomifensine) is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC₅₀ values of 6.6 nM, 48 nM and 830 nM, and K_i values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine shows low or ineffective binding activity to dopamine D2, α1-adrenergic, 5-HT2, and muscarinic receptors. Nomifensine has antidepressive effects .

HY-B0602S3

Desvenlafaxine-d10

Desvenlafaxine-d₁₀ is deuterium labeled Desvenlafaxine. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81165

	Dopamine Transporter Antibody DA transporter; DAT 1; DAT; DAT1; SC6A3_HUMAN; SLC6A3; Sodium dependent dopamine transporter; Sodium-dependent dopamine transporter; Solute carrier family 6 (neurotransmitter transporter dopamine), member 3; Solute carrier family 6 member 3; Variable number tandem repeat (VNTR); dopamine transporter; ADAT 1; Adenosine deaminase tRNA specific 1; HADAT1; tRNA specific adenosine deaminase 1.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat
	Dopamine Transporter Antibody is an unconjugated, approximately 68 kDa, rabbit-derived, anti-Dopamine Transporter polyclonal antibody. Dopamine Transporter Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: dog, cow background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-14197A

Clorgyline hydrochloride 4 Publications Verification		Alkynes
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research, structurally related to Pargyline (HY-A0091A). Clorgyline hydrochloride has little effect on the amounts of conjugated dopamine (DA) present in superfusate of slices from rat striatum. Clorgyline hydrochloride contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks